United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $438.30, for a total value of $1,753,200.00. Following the completion of the sale, the chief executive officer owned 130 shares in the company, valued at approximately $56,979. This trade represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Down 0.3%

Shares of NASDAQ:UTHR traded down $1.33 during midday trading on Tuesday, reaching $437.33. The company had a trading volume of 601,802 shares, compared to its average volume of 598,006. The business’s 50 day moving average price is $412.73 and its 200 day moving average price is $339.81. The stock has a market cap of $18.83 billion, a PE ratio of 16.57, a P/E/G ratio of 4.96 and a beta of 0.66. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $479.50.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.39 earnings per share. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on UTHR shares. HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. UBS Group boosted their price target on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research report on Monday, September 29th. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research report on Thursday, October 30th. Oppenheimer upped their target price on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of United Therapeutics in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $501.90.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its position in United Therapeutics by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 111,861 shares of the biotechnology company’s stock worth $34,483,000 after purchasing an additional 309 shares during the last quarter. IFM Investors Pty Ltd raised its position in United Therapeutics by 5.9% during the 1st quarter. IFM Investors Pty Ltd now owns 8,682 shares of the biotechnology company’s stock worth $2,676,000 after purchasing an additional 484 shares during the last quarter. Brookstone Capital Management bought a new position in United Therapeutics during the 1st quarter worth $1,479,000. World Investment Advisors raised its position in United Therapeutics by 79.2% during the 1st quarter. World Investment Advisors now owns 2,328 shares of the biotechnology company’s stock worth $718,000 after purchasing an additional 1,029 shares during the last quarter. Finally, Concurrent Investment Advisors LLC bought a new position in United Therapeutics during the 1st quarter worth $227,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.